5292-49-9

Usage

General Description

2-Amino-5-fluoroterephthalic acid dimethyl ester is a chemical compound with the molecular formula C10H9FNO4. It is used in the production of pharmaceuticals, dyes, and polymers. This chemical is a derivative of terephthalic acid, a common building block of various polymers such as polyethylene terephthalate (PET). The presence of the amino and fluorine groups in 2-Amino-5-fluoroterephthalic acid dimethyl ester makes it an important ingredient in the synthesis of complex organic molecules. It is also used as a fluorescent probe in biochemical and pharmaceutical research. 2-Amino-5-fluoroterephthalicaciddimethylester has potential applications in a wide range of industries, making it a valuable and versatile chemical.

Upstream product

• 5292-48-8 2-fluoro-5-nitro-terephthalic acid dimethyl ester 
• 5292-47-7 1,4-dimethyl 2-fluorobenzene-1,4-dicarboxylate 

Downstream Products

• 566158-06-3 2-fluoro-5-phenylamino-terephthalic acid dimethyl ester 
• 566158-69-8 2-fluoro-N-(2-(3-(methylthio)phenyl)propan-2-yl)-9-oxo-9,10-dihydroacridine-3-carboxamide 
• 566160-51-8 C₂₄H₂₁FN₂O₂S 
• 566158-07-4 2-fluoro-5-phenylamino-terephthalic acid 

Relevant academic research and scientific papers

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: Discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1- yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)

Inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides, catalyzes the irreversible nicotinamide-adenine dinucleotide dependent oxidation of inosine-5′- monophosphate to xanthosine-5′-monophosphate. Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clinical utility for the treatment of transplant rejection based on its inhibition of IMPDH. The overall clinical benefit of MMF is limited by what is generally believed to be compound-based, dose-limiting gastrointestinal (GI) toxicity that is related to its specific pharmacokinetic characteristics. Thus, development of an IMPDH inhibitor with a novel structure and a different pharmacokinetic profile may reduce the likelihood of GI toxicity and allow for increased efficacy. This article will detail the discovery and SAR leading to a novel and potent acridone-based IMPDH inhibitor 4m and its efficacy and GI tolerability when administered orally in a rat adjuvant arthritis model.